A MAGE-3 peptide presented by HLA-B44 is also recognized by cytolytic T lymphocytes on HLA-B18.

Antigens encoded by MAGE genes are of particular interest for cancer immunotherapy because of their tumoral specificity and because they are shared by many tumors. Antigenic peptide MEVDPIGHLY, which is encoded by MAGE-3 and is known to be presented by human leukocyte antigen (HLA)-B44, is currently being used in therapeutic vaccination trials. We report here that a cytolytic T lymphocyte (CTL) clone, which is restricted by HLA-B*1801, recognizes the same peptide and, importantly, lyzes HLA-B18 tumor cells expressing MAGE-3. These results imply that the use of peptide MEVDPIGHLY can now be extended to HLA-B18 patients. We also provide evidence that, under limiting amounts of protein MAGE-3, HLA B*1801 and B*4403 compete for binding to the peptide.

[1]  B. Malissen,et al.  Structural and genetic analyses of HLA class I molecules using monoclonal xenoantibodies. , 2008, Tissue antigens.

[2]  M. Bertrand,et al.  An overview of the MAGE gene family with the identification of all human members of the family. , 2001, Cancer research.

[3]  P. Bruggen,et al.  A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. , 2001, Tissue antigens.

[4]  C. Voorter,et al.  Unexpected Bw4 and Bw6 reactivity patterns in new alleles. , 2000, Tissue antigens.

[5]  J. Tine,et al.  A MAGE-A1 peptide presented to cytolytic T lymphocytes by both HLA-B35 and HLA-A1 molecules. , 2000, Tissue antigens.

[6]  C. Bony,et al.  Identification in humans of HPV‐16 E6 and E7 protein epitopes recognized by cytolytic T lymphocytes in association with HLA‐B18 and determination of the HLA‐B18‐specific binding motif , 2000, European journal of immunology.

[7]  P. van der Bruggen,et al.  A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. , 2000, Tissue antigens.

[8]  G. Cornelis,et al.  Identification of five MAGE-A1 epitopes recognized by cytolytic T lymphocytes obtained by in vitro stimulation with dendritic cells transduced with MAGE-A1. , 1999, Journal of immunology.

[9]  P. Dalerba,et al.  Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family. , 1999, Cancer research.

[10]  K. Itoh,et al.  A newly identified MAGE‐3‐derived epitope recognized by HLA‐A24‐restricted cytotoxic T lymphocytes , 1999, International journal of cancer.

[11]  A. Eggermont,et al.  Identification of MAGE-3 Epitopes Presented by HLA-DR Molecules to CD4+ T Lymphocytes , 1999, The Journal of experimental medicine.

[12]  P. Coulie,et al.  Differences in the recognition by CTL of peptides presented by the HLA-B*4402 and the HLA-B*4403 molecules which differ by a single amino acid. , 1999, Tissue antigens.

[13]  G. Cornelis.  The Yersinia Deadly Kiss , 1998, Journal of bacteriology.

[14]  G. Cornelis,et al.  Role of YopP in Suppression of Tumor Necrosis Factor Alpha Release by Macrophages during YersiniaInfection , 1998, Infection and Immunity.

[15]  K. Arden,et al.  Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. , 1998, Cancer research.

[16]  A. Monaco,et al.  Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins. , 1997, Genomics.

[17]  A. Sette,et al.  Induction of antitumor cytotoxic T lymphocytes with a MAGE-3-encoded synthetic peptide presented by human leukocytes antigen-A24. , 1997, Cancer research.

[18]  G. Cornelis,et al.  Virulence and arsenic resistance in Yersiniae , 1997, Journal of bacteriology.

[19]  F. Marincola,et al.  Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. , 1995, Immunology today.

[20]  R. Mulligan,et al.  Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Rowland-Jones,et al.  Different MHC class I alleles compete for presentation of overlapping viral epitopes. , 1995, Immunity.

[22]  G. Cornelis,et al.  Translocation of a hybrid YopE‐adenylate cyclase from Yersinia enterocolitica into HeLa cells , 1994, Molecular microbiology.

[23]  P. Bruggen,et al.  Autologous cytolytic T lymphocytes recognize a MAGE‐1 nonapeptide on melanomas expressing HLA‐Cw* 1601 , 1994, European journal of immunology.

[24]  P. Romero,et al.  Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes , 1994, The Journal of experimental medicine.

[25]  Catia,et al.  A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E , 1992, The Journal of experimental medicine.

[26]  M. Perricaudet,et al.  Widespread long-term gene transfer to mouse skeletal muscles and heart. , 1992, The Journal of clinical investigation.

[27]  W. Fiers,et al.  Lithium chloride potentiates tumor necrosis factor-mediated cytotoxicity in vitro and in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[28]  R. Demars,et al.  Production of human cells expressing individual transferred HLA-A,-B,-C genes using an HLA-A,-B,-C null human cell line. , 1989, Journal of immunology.

[29]  C. Uyttenhove,et al.  Interleukin-HP1, a T cell-derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas , 1987, The Journal of experimental medicine.

[30]  T. Espevik,et al.  A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from human monocytes. , 1986, Journal of immunological methods.

[31]  C. Barnstable,et al.  Use of a monoclonal antibody (W6/32) in structural studies of HLA-A,B,C, antigens. , 1979, Journal of immunology.

[32]  F. Graham,et al.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.

[33]  L. Old,et al.  Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous cytolytic T lymphocytes , 2004, Immunogenetics.

[34]  A. Sette,et al.  The multi-epitope approach for immunotherapy for cancer: identification of several CTL epitopes from various tumor-associated antigens expressed on solid epithelial tumors. , 1998, Human immunology.

[35]  F. Garrido,et al.  HLA class I antigens in human tumors. , 1995, Advances in cancer research.